Literature DB >> 30902844

Hepatosplenic T cell lymphoma presenting as multiorgan failure.

Puraskar Pateria1,2, Annalise Martin3, Tze Sheng Khor4, Vanoo Jayasekeran5.   

Abstract

A 59-year-oldwoman presented with a 2-month history of malaise, abdominal distention and unintentional weight loss. She was initially managed as community acquired pneumonia with a suspicion of underlying chronic liver disease but she deteriorated rapidly into a multiorgan failure necessitating transfer to intensive care unit of a tertiary hospital. She was investigated with liver and bone marrow biopsy that confirmed the diagnosis of hepatosplenic T cell lymphoma. She was treated with cyclophosphamide, doxorubicin, vincristine, etoposide and prednisolone chemotherapy that was changed to salvage ifosfamide carboplatin etoposide (ICE) chemotherapy due to poor response with first-line chemotherapy and disease progression. Unfortunately, her disease progressed further and she opted for palliative management. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; carcinogenesis; chemotherapy

Mesh:

Year:  2019        PMID: 30902844      PMCID: PMC6453275          DOI: 10.1136/bcr-2018-228186

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Authors:  David S Kotlyar; Mark T Osterman; Robert H Diamond; David Porter; Wojciech C Blonski; Mariusz Wasik; Sami Sampat; Manuel Mendizabal; Ming V Lin; Gary R Lichtenstein
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-01       Impact factor: 11.382

2.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

3.  Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Sa A Wang; Guilin Tang; Carlos E Bueso-Ramos; Jeffrey L Jorgensen; Govind Bhagat; Weina Chen; Shaoying Li; Ken H Young; Roberto N Miranda
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

4.  Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.

Authors:  Musa Drini; Peter J Prichard; Gregor J E Brown; Finlay A Macrae
Journal:  Med J Aust       Date:  2008-10-20       Impact factor: 7.738

Review 5.  Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?

Authors:  K Subramaniam; D Yeung; F Grimpen; J Joseph; K Fay; M Buckland; D Talaulikar; J Elijah; A C Clarke; P Pavli; J Moore
Journal:  Intern Med J       Date:  2014-03       Impact factor: 2.048

6.  Hepatosplenic and other gammadelta T-cell lymphomas.

Authors:  Francisco Vega; L Jeffrey Medeiros; Philippe Gaulard
Journal:  Am J Clin Pathol       Date:  2007-06       Impact factor: 2.493

Review 7.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.